MEDEX, Inc.

(A Development Stage Company)

FINANCIAL STATEMENTS

June 30, 2012

Unaudited

MEDEX, Inc.
(A Development Stage Company)

BALANCE SHEET
Unaudited

		June 30, 2012		March 31, 2012
ASSETS				
CURRENT ASSETS				
Cash	$	60,000	$	60,000
TOTAL CURRENT ASSETS		60,000		60,000
OTHER ASSETS				
Investment in Subsidiaries		312,767		312,767
Deposits		-		-
TOTAL ASSETS	$	372,767	$	372,767
LIABILITIES AND STOCKHOLDERS' DEFICIT				
CURRENT LIABILITIES				
Due to Related Party	$	90,609	$	84,609
TOTAL CURRENT LIABILITIES		90,609		84,609
STOCKHOLDERS' DEFICIT				
Common Stock, $0.001 par value				
Authorized				
100,000,000 shares of common stock, $0.001 par value,				
Issued and outstanding				
84,640,000 shares of common stock	$	84,640	$	84,640
Subscription Receivable		(64,640)		(64,640)
Deficit accumulated during the exploration stage		262,158		268,158
TOTAL STOCKHOLDER'S DEFICIT	$	282,158	$	288,158
TOTAL LIABILITIES AND STOCKHOLDER'S DEFICIT	$	372,767	$	372,767

The accompanying notes are an integral part of these financial statements.

MEDEX, Inc.

(A Development Stage Company)

STATEMENT OF OPERATIONS
Unaudited

	3 months ended June 30, 2012	3 months ended June 30, 2011	Cumulative results from inception (June 29, 1998) to June 30, 2012
REVENUE			
Revenues	$ -	$ -	$ -
Total revenues	-	-	-
EXPENSES			
Interest payable	$ (6,000)	$ (5,500)	$ (14,500)
Gain on non-consolidation of subsidiaries	-	-	276,658
Total expenses	(6,000)	(5,500)	262,158
NET LOSS	$ (6,000)	$ (5,500)	$ 262,158
LOSS PER COMMON SHARE - Basic and diluted	$ 0.00	$ 0.00	
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	84,640,000	84,640,000	

The accompanying notes are an integral part of these financial statements.

NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION

The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations at June 30, 2012, and for all periods presented herein, have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. The results of operations for the periods ended June 30, 2012 and the same period last year are not necessarily indicative of the operating results for the full years.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars

Cash and Cash Equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Financial Instruments

The carrying value of the Company's financial instruments approximates their fair value because of the short maturity of these instruments.

Basic and Diluted Net Loss per Share

The Company computes loss per share in accordance with "ASC-260", "Earnings per Share" which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. The Company has no potential dilutive instruments and accordingly basic loss and diluted loss per share are the same.

NOTE 3 – GOING CONCERN

The Company's financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company does not currently have an established ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management's plan is to obtain such resources for the Company by obtaining capital from management and significant shareholders sufficient to meet its minimal operating expenses and seeking equity and/or debt financing. However management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

NOTE 4 – RELATED PARTY TRANSACTIONS

On April 17 2011, a demand loan was made to the company of $60,000 at 20% interest.
The agreement was made October 1st, 2012, by and between Vanguard, a corporation ("Assignor"), and between James Neal, ("Assignee"). The assignor is a creditor to Medex, Inc. ("Debtor"), and is the Holder of a debt that accrued on the books of Debtor on April 17,2011 in the principal amount of $60,000.00 (the "Debt").